Exacis Biotherapeutics Announces Key Additions To Company’s Scientific Advisory Board

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced the addition of three oncology and cell therapy experts to its Scientific Advisory Board (SAB): Pamela Munster, MD; Caron Jacobson, MD, MMSc; and...

Click to view original post